PROTEOMICS Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PROTEOMICS

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jongmans who started this subject	5/4/2001 6:08:53 AM
From: nigel bates	Read Replies (1) of 539

Another player in high throughput X-Ray crystallography - astex-technology.com UK based, apparently uses the synchrotron at Grenoble. Raised £23m this week. nig Financial Times; May 4, 2001 By DAVID FIRN Astex, a start-up bio-technology company, has raised £23m to turn one of the oldest tools of biochemistry into a drug discovery platform aimed at finding potentially toxic drugs before they enter development... Astex was set up in 1999 to commercialise the work of Prof Tom Blundell, head of biochemistry at Cambridge University, with seed funding from Abingworth Management and Oxford Biosciences, which participated in the latest round of funding.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next